Bristol-Myers Squibb Company (BMY)vsAnheuser Busch Inbev NV ADR (BUD)
BMY
Bristol-Myers Squibb Company
$56.16
-0.16%
HEALTHCARE · Cap: $114.68B
BUD
Anheuser Busch Inbev NV ADR
$79.89
-0.45%
CONSUMER DEFENSIVE · Cap: $159.00B
Smart Verdict
WallStSmart Research — data-driven comparison
Anheuser Busch Inbev NV ADR generates 26% more annual revenue ($60.96B vs $48.48B). BMY leads profitability with a 15.0% profit margin vs 11.9%. BUD appears more attractively valued with a PEG of 1.78. BUD earns a higher WallStSmart Score of 63/100 (C+).
BMY
Buy60
out of 100
Grade: C+
BUD
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+32.0%
Fair Value
$88.08
Current Price
$56.16
$31.92 discount
Margin of Safety
-9.4%
Fair Value
$70.63
Current Price
$79.89
$9.26 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 39 in profit
Strong operational efficiency at 33.0%
Large-cap with strong market position
Attractively priced relative to earnings
Large-cap with strong market position
Strong operational efficiency at 26.7%
Earnings expanding 20.3% YoY
Areas to Watch
2.6% revenue growth
Expensive relative to growth rate
Distress zone — elevated risk
Elevated debt levels
Expensive relative to growth rate
Trading at 10.7x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : BMY
The strongest argument for BMY centers on Return on Equity, Operating Margin, Market Cap.
Bull Case : BUD
The strongest argument for BUD centers on Market Cap, Operating Margin, EPS Growth. Revenue growth of 12.0% demonstrates continued momentum.
Bear Case : BMY
The primary concerns for BMY are Revenue Growth, PEG Ratio, Altman Z-Score. Debt-to-equity of 2.55 is elevated, increasing financial risk.
Bear Case : BUD
The primary concerns for BUD are PEG Ratio, Price/Book.
Key Dynamics to Monitor
BUD carries more volatility with a beta of 0.79 — expect wider price swings.
BUD is growing revenue faster at 12.0% — sustainability is the question.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
BUD scores higher overall (63/100 vs 60/100) and 12.0% revenue growth. BMY offers better value entry with a 32.0% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Bristol-Myers Squibb Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
Visit Website →Anheuser Busch Inbev NV ADR
CONSUMER DEFENSIVE · BEVERAGES - BREWERS · USA
Anheuser-Busch InBev SA / NV is engaged in the production, distribution and sale of beer, alcoholic beverages and soft drinks worldwide.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?